Generic placeholder image

Current Molecular Medicine

Author(s): Moustafa M. Mohammed, Ahmed M. M. Okasha, Amany H. Abdel Naiem, Reham F. Mohamed, Sayed F. Abdelwahab* and Hatem A. Mohamed

DOI: 10.2174/1566524022666220106154111

DownloadDownload PDF Flyer Cite As
Cyclosporine Ameliorates Silica-Induced Autoimmune Hepatitis in Rat Model by Altering the Expression of Toll-Like Receptor-4, Interleukin-2, and Tumor Necrosis Factor-α

Page: [87 - 95] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Background: Autoimmune hepatitis (AIH) is an inflammatory liver disease that is characterized histologically by interface hepatitis, biochemically by elevated transaminase levels, and serologically by the presence of autoantibodies. Toll-like receptor (TLR)-4 is a TLR family member that, upon activation in hepatocytes, initiates a cascade of events. Interleukin-2 (IL-2) and tumour necrosis factor α (TNF-α) are potent inflammatory cytokines secreted in AIH, playing an important role in the early development of inflammation and hepatocyte damage.

Objectives: This study examined the role of cyclosporine in AIH and illustrated its actions on altered hepatic function in the silica-induced AIH model.

Methods: AIH was induced in Wistar rats using sodium silicate. The rats were divided into four groups: the control group, silica-AIH group, cyclosporine-treated group, and prevention group. TLR-4 and IL-2 mRNA expressions in liver tissues were tested by RTPCR.

Results: AIH was associated with up-regulation of liver enzymes, IL-2 and TLR-4 gene expression, while cyclosporine significantly down-regulated the expression of both. The relative quantity of TLR-4 mRNA was 1±0, 13.57±1.91, 4±0.38, and 2±0 in control, AIH, cyclosporine, and prevention groups, respectively (p<0.001). Also, the relative quantity of IL-2 mRNA was 1±0, 14.79±1.42, 7.07±0.96, and 3.4±0.55 in control, AIH, cyclosporine, and prevention groups, respectively (p<0.001). Additionally, immunohistochemical staining for TNF-α in liver sections was increased in the silica-AIH group but was found to decrease in the cyclosporine-treated and prevention groups.

Conclusion: This study advocates the therapeutic role of cyclosporine in treating immune-mediated hepatic diseases. Cyclosporine improves histological alterations in the liver and inhibits the production of proinflammatory cytokines.

Keywords: Autoimmune hepatitis, cyclosporine, interleukin 2, NFkB, TLR-4, TNF-a.

[1]
Wen L, Ma Y, Bogdanos DP, et al. Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Mol Med 2001; 1(3): 379-89.
[http://dx.doi.org/10.2174/1566524013363672] [PMID: 11899084]
[2]
Sucher E, Sucher R, Gradistanac T, Brandacher G, Schneeberger S, Berg T. Autoimmune hepatitis—immunologically triggered liver pathogenesis—diagnostic and therapeutic strategies. J Immunol Res 2019; 2019: 9437043.
[http://dx.doi.org/10.1155/2019/9437043] [PMID: 31886312]
[3]
Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002; 35(1): 7-13.
[http://dx.doi.org/10.1053/jhep.2002.30991] [PMID: 11786954]
[4]
Pimentel-Nunes P, Soares JB, Roncon-Albuquerque R Jr, Dinis-Ribeiro M, Leite-Moreira AF. Toll-like receptors as therapeutic targets in gastrointestinal diseases. Expert Opin Ther Targets 2010; 14(4): 347-68.
[http://dx.doi.org/10.1517/14728221003642027] [PMID: 20146632]
[5]
Farrell GC, Haczeyni F, Chitturi S. Pathogenesis of NASH: How metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease obesity, fatty liver and liver cancer. Adv Exp Med Biol 2018; 1061: 19-44.
[http://dx.doi.org/10.1007/978-981-10-8684-7_3] [PMID: 29956204]
[6]
Sun L, Dai JJ, Hu WF, Wang J. Expression of toll-like receptors in hepatic cirrhosis and hepatocellular carcinoma. Genet Mol Res 2016; 15(2): 1-15.
[http://dx.doi.org/10.4238/gmr.15027419] [PMID: 27420991]
[7]
Hösel M, Broxtermann M, Janicki H, et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 2012; 55(1): 287-97.
[http://dx.doi.org/10.1002/hep.24625] [PMID: 21898480]
[8]
Vaikunthanathan T, Safinia N, Lombardi G, Lechler RI. Microbiota, immunity and the liver. Immunol Lett 2016; 171: 36-49.
[http://dx.doi.org/10.1016/j.imlet.2016.01.008] [PMID: 26835593]
[9]
Shen M, Lu J, Cheng P, et al. Ethyl pyruvate pretreatment attenuates concanavalin a-induced autoimmune hepatitis in mice. PLoS One 2014; 9(2): e87977.
[http://dx.doi.org/10.1371/journal.pone.0087977] [PMID: 24498418]
[10]
Ho I-C, Kim J, Szabo S, Glimcher L, Eds. Tissue-specific regulation of cytokine gene expression. Cold Spring Harb Symp Quant Biol 1999; 64: 573-84.
[http://dx.doi.org/10.1101/sqb.1999.64.573] [PMID: 11232334]
[11]
Brown JM, Archer AJ, Pfau JC, Holian A. Silica accelerated systemic autoimmune disease in lupus-prone New Zealand mixed mice. Clin Exp Immunol 2003; 131(3): 415-21.
[http://dx.doi.org/10.1046/j.1365-2249.2003.02094.x] [PMID: 12605693]
[12]
Biburger M, Tiegs G. α-galactosylceramide-induced liver injury in mice is mediated by TNF-α but independent of Kupffer cells. J Immunol 2005; 175(3): 1540-50.
[http://dx.doi.org/10.4049/jimmunol.175.3.1540] [PMID: 16034092]
[13]
Al-Mogairen SM, Al-Arfaj AS, Meo SA, Adam M, Al-Hammad A, Gad El Rab MO. Induction of autoimmunity in Brown Norway rats by oral and parenteral administration of sodium silicate. Lupus 2009; 18(5): 413-7.
[http://dx.doi.org/10.1177/0961203308098192] [PMID: 19318393]
[14]
Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46(6): 1321-7.
[http://dx.doi.org/10.1023/A:1010683817344] [PMID: 11414311]
[15]
Atta H, El-Rehany M, Hammam O, et al. Mutant MMP-9 and HGF gene transfer enhance resolution of CCl4-induced liver fibrosis in rats: role of ASH1 and EZH2 methyltransferases repression. PLoS One 2014; 9(11): e112384.
[http://dx.doi.org/10.1371/journal.pone.0112384] [PMID: 25380300]
[16]
Barbas CF, Burton DR, Scott JK, Silverman GJ. Quantitation of DNA and RNA. CSH Protoc 2007; 2007: pdb. ip47.
[http://dx.doi.org/10.1101/pdb.ip47]
[17]
VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques 2008; 44(5): 619-26.
[http://dx.doi.org/10.2144/000112776] [PMID: 18474036]
[18]
Kim S, Kim SY, Pribis JP, et al. Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol Med 2013; 19(1): 88-98.
[http://dx.doi.org/10.2119/molmed.2012.00306] [PMID: 23508573]
[19]
Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34(12): 1705-9.
[http://dx.doi.org/10.1136/gut.34.12.1705] [PMID: 8031350]
[20]
Kasprzak A, Zabel M, Biczysko W, et al. Expression of cytokines (TNF-α, IL-1α, and IL-2) in chronic hepatitis C: Comparative hybridocytochemical and immunocytochemical study in children and adult patients. J Histochem Cytochem 2004; 52(1): 29-38.
[http://dx.doi.org/10.1177/002215540405200104] [PMID: 14688215]
[21]
Chen J, Eslick G, Weltman M. Systematic review with meta‐analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Aliment Pharmacol Ther 2014; 39(2): 117-24.
[http://dx.doi.org/10.1111/apt.12563] [PMID: 24261965]
[22]
Parks CG, Cooper GS. Occupational exposures and risk of systemic lupus erythematosus: A review of the evidence and exposure assessment methods in population- and clinic-based studies. Lupus 2006; 15(11): 728-36.
[http://dx.doi.org/10.1177/0961203306069346] [PMID: 17153843]
[23]
Kuroda E, Ishii KJ, Uematsu S, et al. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 2011; 34(4): 514-26.
[http://dx.doi.org/10.1016/j.immuni.2011.03.019] [PMID: 21497116]
[24]
Okamoto T, Kobayashi T. Effects of immunosuppressants on concanavalin A-induced interleukin-2 mRNA expression in mouse liver. Jpn J Pharmacol 1998; 77(3): 261-3.
[http://dx.doi.org/10.1254/jjp.77.261] [PMID: 9717775]
[25]
Tajiri N, Borlongan CV, Kaneko Y. therapeutics. Cyclosporine a treatment abrogates ischemia‐induced neuronal cell death by preserving mitochondrial integrity through upregulation of the Parkinson's disease‐associated protein DJ‐1. CNS Neurosci 2016; 22(7): 602-10.
[http://dx.doi.org/10.1111/cns.12546] [PMID: 27247192]
[26]
Al-Mogairen SM, Al Sheikh A, Husain S, et al. Effect of exposure to silica in inducing autoimmune hepatitis: An experimental animal-controlled study. Eur Rev Med Pharmacol Sci 2015; 19(20): 3881-5.
[PMID: 26531274]
[27]
Zhai K-F, Duan H, Cao W-G, et al. Protective effect of Rabdosia amethystoides (Benth) Hara extract on acute liver injury induced by concanavalin A in mice through inhibition of TLR4-NF-κB signaling pathway. J Pharmacol Sci 2016; 130(2): 94-100.
[http://dx.doi.org/10.1016/j.jphs.2015.12.006] [PMID: 26823124]
[28]
O’Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O’Neill EA. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992; 357(6380): 692-4.
[http://dx.doi.org/10.1038/357692a0] [PMID: 1377361]
[29]
Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80(3 Pt 2): S40-5.
[http://dx.doi.org/10.1006/clin.1996.0140] [PMID: 8811062]
[30]
Howell J, Sawhney R, Testro A, et al. Cyclosporine and tacrolimus have inhibitory effects on toll-like receptor signaling after liver transplantation. Liver Transpl 2013; 19(10): 1099-107.
[http://dx.doi.org/10.1002/lt.23712] [PMID: 23894100]
[31]
Kang YJ, Kusler B, Otsuka M, et al. Calcineurin negatively regulates TLR-mediated activation pathways. J Immunol 2007; 179(7): 4598-607.
[http://dx.doi.org/10.4049/jimmunol.179.7.4598] [PMID: 17878357]
[32]
Jennings C, Kusler B, Jones PP. Calcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivo. Innate Immun 2009; 15(2): 109-20.
[http://dx.doi.org/10.1177/1753425908100928] [PMID: 19318421]
[33]
Zhang X, Wei H-X, Rui S, Wei H, Tian Z. Opposite effects of high and low doses of interleukin-2 on T cell-mediated hepatitis in mice (interleukin-2 on hepatitis). Hepatol Int 2010; 4(3): 641-8.
[http://dx.doi.org/10.1007/s12072-010-9196-0] [PMID: 21063489]
[34]
Guven-Maiorov E, Keskin O, Gursoy A, Nussinov R. A structural view of negative regulation of the toll-like receptor-mediated inflammatory pathway. Biophys J 2015; 109(6): 1214-26.
[http://dx.doi.org/10.1016/j.bpj.2015.06.048] [PMID: 26276688]
[35]
Vespasiani-Gentilucci U, Carotti S, Onetti-Muda A, et al. Toll-like receptor-4 expression by hepatic progenitor cells and biliary epithelial cells in HCV-related chronic liver disease. Mod Pathol 2012; 25(4): 576-89.
[http://dx.doi.org/10.1038/modpathol.2011.197] [PMID: 22173288]
[36]
Robak T, Gladalska A, Stepień H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998; 9(2): 145-54.
[PMID: 9681390]
[37]
Chen Q, Xue Y, Sun J. Kupffer cell-mediated hepatic injury induced by silica nanoparticles in vitro and in vivo. Int J Nanomedicine 2013; 8: 1129-40.
[PMID: 23515466]